Leap Therapeutics Inc
LPTX0.360USD
+0.054+17.58%
取引時間 （ET）15分遅れの株価
14.91M時価総額
損失額直近12ヶ月PER
詳細情報 Leap Therapeutics Inc 企業名
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
企業情報
企業コードLPTX
会社名Leap Therapeutics Inc
上場日Jan 24, 2017
最高経営責任者「CEO」Mr. Douglas E. (Doug) Onsi
従業員数52
証券種類Ordinary Share
決算期末Jan 24
本社所在地47 Thorndike St, Suite B1-1
都市CAMBRIDGE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号02141
電話番号16177140360
ウェブサイトhttps://www.leaptx.com/
企業コードLPTX
上場日Jan 24, 2017
最高経営責任者「CEO」Mr. Douglas E. (Doug) Onsi
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
108.28K
+2.01%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Chairman of the Board
Chairman of the Board
23.05K
+10.21%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
-60.52%
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
--
--
Ms. Patricia (Patty) Martin
Ms. Patricia (Patty) Martin
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
108.28K
+2.01%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Chairman of the Board
Chairman of the Board
23.05K
+10.21%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
-60.52%
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, May 17
更新時刻: Sat, May 17
株主統計
種類
株主統計
株主統計
比率
Gilead Sciences Inc
12.84%
Samsara BioCapital, LLC
5.89%
683 Capital Management LLC
3.50%
Acadian Asset Management LLC
3.09%
Beigene Ltd
2.93%
Other
71.75%
株主統計
株主統計
比率
Gilead Sciences Inc
12.84%
Samsara BioCapital, LLC
5.89%
683 Capital Management LLC
3.50%
Acadian Asset Management LLC
3.09%
Beigene Ltd
2.93%
Other
71.75%
種類
株主統計
比率
Corporation
15.77%
Investment Advisor
10.39%
Venture Capital
7.58%
Hedge Fund
6.52%
Investment Advisor/Hedge Fund
4.34%
Individual Investor
0.58%
Research Firm
0.19%
Pension Fund
0.03%
Other
54.60%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
120
18.82M
45.42%
-6.51M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
2023Q2
173
10.09M
52.77%
+1.83M
2023Q1
168
6.01M
55.14%
-976.73K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Gilead Sciences Inc
5.32M
12.84%
--
--
Apr 21, 2025
Samsara BioCapital, LLC
2.44M
5.89%
--
--
Apr 21, 2025
683 Capital Management LLC
1.45M
3.5%
+99.90K
+7.40%
Mar 31, 2025
Acadian Asset Management LLC
1.28M
3.09%
+1.06M
+470.43%
Mar 31, 2025
Beigene Ltd
1.22M
2.93%
+1.22M
--
Oct 31, 2024
The Vanguard Group, Inc.
1.18M
2.84%
-15.38K
-1.29%
Mar 31, 2025
Monaco asset management S.A.M.
1.05M
2.53%
+844.13K
+410.02%
Mar 31, 2025
Simplify Asset Management Inc
950.97K
2.29%
+4.93K
+0.52%
Mar 31, 2025
Laurion Capital Management LP
709.22K
1.71%
--
--
Mar 31, 2025
HealthCare Ventures LLC
697.23K
1.68%
+20.91K
+3.09%
Apr 21, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Simplify Health Care ETF
0.19%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
0%
Simplify Health Care ETF
比率0.19%
Avantis US Small Cap Equity ETF
比率0%
DFA Dimensional US Sustainability Core 1 ETF
比率0%
Dimensional US Core Equity 1 ETF
比率0%
iShares Micro-Cap ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
日付
種類
比率
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
